As of Oct 31, 2023, Neutra Corp. had total assets of $26,944 and total liabilities of $962,984. Total assets were down 72.5% from a year earlier. Stockholders' equity was negative, at -$936,040, because liabilities exceed assets. Cash and investments were $692. The current ratio, current assets divided by current liabilities, was 0.02.
USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the same quarter a year earlier.
| Line |
Q3 FY2024
Oct 31, 2023
|
Q2 FY2024
Jul 31, 2023
|
Q1 FY2024
Apr 30, 2023
|
Q4 FY2023
Jan 31, 2023
|
Q3 FY2023
Oct 31, 2022
|
Q2 FY2023
Jul 31, 2022
|
Q1 FY2023
Apr 30, 2022
|
Q4 FY2022
Jan 31, 2022
|
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash |
0
+51.8%
|
0
-95.7%
|
0
-79.3%
|
0
+86.5%
|
0
-98.4%
|
0
+2254.7%
|
0
-18.7%
|
0
-95.5%
|
| Cash and investments |
0
+51.8%
|
0
-95.7%
|
0
-79.3%
|
0
+86.5%
|
0
-98.4%
|
0
+2254.7%
|
0
-18.7%
|
0
-95.5%
|
| Receivables |
0
|
—
|
—
|
—
|
—
|
—
|
—
|
—
|
| Inventory |
0
-30.6%
|
0
-23.5%
|
0
-3.0%
|
0
|
0
|
0
|
0
|
—
|
| Total current assets |
0
-32.8%
|
0
-61.6%
|
0
-36.9%
|
0
+868.3%
|
0
-5.8%
|
0
+707.2%
|
0
+89.4%
|
0
-89.3%
|
| Property and equipment, net |
0
-89.1%
|
0
-81.3%
|
0
-72.7%
|
0
-61.5%
|
0
-53.3%
|
0
-47.0%
|
0
-42.2%
|
0
-22.6%
|
| Total assets |
0
-72.5%
|
0
-74.0%
|
0
-63.3%
|
0
-42.6%
|
0
-45.2%
|
0
-18.6%
|
0
-29.3%
|
0
-31.4%
|
| Liabilities and equity | ||||||||
| Accounts payable |
0
|
0
|
0
|
0
|
—
|
—
|
—
|
—
|
| Total current liabilities |
1
-27.1%
|
1
-28.4%
|
1
-33.3%
|
1
-34.2%
|
1
+18.9%
|
1
+15.2%
|
1
+19.2%
|
1
+15.2%
|
| Total liabilities |
1
-26.0%
|
1
-27.3%
|
1
-29.3%
|
1
-29.5%
|
1
+24.0%
|
1
+20.7%
|
1
+20.0%
|
1
+15.2%
|
| Stockholders' equity |
-1
+25.9%
|
-1
+25.4%
|
-1
+26.8%
|
-1
+39.2%
|
-1
-6.4%
|
-1
-4.0%
|
-1
-5.8%
|
-1
-31.6%
|
| Ratios | ||||||||
| Current ratio |
0.02x
|
0.02x
|
0.03x
|
0.03x
|
0.02x
|
0.04x
|
0.03x
|
0.00x
|
| Return on assets |
-1,758.58%
|
-1,355.20%
|
-972.60%
|
-746.81%
|
-471.80%
|
-394.31%
|
-409.16%
|
-483.40%
|
| Book value per share |
-0.00
|
-0.00
|
-0.00
|
-0.00
|
-0.00
|
-0.00
|
-0.00
|
-0.00
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.
Company profile
- Industry
- Medicinal Chemicals & Botanical Products (SIC 2833)
- Listed as
- NTRR (OTC)
- Fiscal year ends
- January 31
- Incorporated in
- WY
- Headquarters
- Houston, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1512886
Other Medicinal Chemicals & Botanical Products companies
- Definium Therapeutics, Inc. DFTX
- Regencell Bioscience Holdings Ltd RGC
- Curaleaf Holdings, Inc. CURLF
- Trulieve Cannabis Corp. TRLV
- Cronos Group Inc. CRON
- TFA Therapeutics, Inc. RAJAF
- Tilray Brands, Inc. TLRY
- SNDL Inc. SNDL
Source: SEC EDGAR filings. This is company-reported data, not investment advice.